Treatment of lupus nephritis

References

• Hahn BH. Antibodies to DNA. N. Engl. J. Med.338(19), 1359–1368 (1998).
   PubMed Web of Science ®Google Scholar
• Doria A, Iaccarino L, Ghirardello A et al. Long-term prognosis and causes of death in systemic lupus erythematosus. Am. J. Med.119(8), 700–706 (2006).
   PubMed Web of Science ®Google Scholar
• Bono L, Cameron JS, Hicks JA. The very long-term prognosis and complications of lupus nephritis and its treatment. Q. J. Med.92(4), 211–218 (1999).
   Google Scholar
• Berden JH. Lupus nephritis. Kidney Int.52(2), 538–558 (1997).
   PubMed Web of Science ®Google Scholar
• Winfield JB, Faiferman I, Koffler D. Avidity of anti-DNA antibodies in serum and IgG glomerular eluates from patients with systemic lupus erythematosus. Association of high avidity antinative DNA antibody with glomerulonephritis. J. Clin. Invest.59(1), 90–96 (1977).
   PubMed Web of Science ®Google Scholar
• Pankewycz OG, Migliorini P, Madaio MP. Polyreactive autoantibodies are nephritogenic in murine lupus nephritis. J. Immunol.139(10), 3287–3294 (1987).
   PubMed Web of Science ®Google Scholar
• van Bruggen MC, Kramers C, Hylkema MN, Smeenk RJ, Berden JH. Significance of anti-nuclear and anti-extracellular matrix autoantibodies for albuminuria in murine lupus nephritis; a longitudinal study on plasma and glomerular eluates in MRL/l mice. Clin. Exp. Immunol.105(1), 132–139 (1996).
   PubMed Web of Science ®Google Scholar
• Faaber P, Rijke TP, van de Putte LB, Capel PJ, Berden JH. Cross-reactivity of human and murine anti-DNA antibodies with heparan sulfate. The major glycosaminoglycan in glomerular basement membranes. J. Clin. Invest.77(6), 1824–1830 (1986).
   PubMed Web of Science ®Google Scholar
• van Bavel CC, Fenton KA, Rekvig OP, van der Vlag J, Berden JH. Glomerular targets of nephritogenic autoantibodies in systemic lupus erythematosus. Arthritis Rheum.58(7), 1892–1899 (2008).
   PubMedGoogle Scholar
• Nagafuchi H, Shimoyama Y, Kashiwakura J, Takeno M, Sakane T, Suzuki N. Preferential expression of B7.2 (CD86), but not B7.1 (CD80), on B cells induced by CD40/CD40L interaction is essential for anti-DNA autoantibody production in patients with systemic lupus erythematosus. Clin. Exp. Rheumatol.21(1), 71–77 (2003).
   PubMed Web of Science ®Google Scholar
• Bijl M, Horst G, Limburg PC, Kallenberg CG. Expression of costimulatory molecules on peripheral blood lymphocytes of patients with systemic lupus erythematosus. Ann. Rheum. Dis.60(5), 523–526 (2001).
   PubMed Web of Science ®Google Scholar
• Patschan S, Dolff S, Kribben A et al. CD134 expression on CD4+ T cells is associated with nephritis and disease activity in patients with systemic lupus erythematosus. Clin. Exp. Immunol.145(2), 235–242 (2006).
   PubMed Web of Science ®Google Scholar
• Enghard P, Humrich JY, Rudolph B et al. CXCR3+CD4+ T cells are enriched in inflamed kidneys and urine and provide a new biomarker for acute nephritis flares in systemic lupus erythematosus patients. Arthritis Rheum.60(1), 199–206 (2009).
   PubMedGoogle Scholar
• Dolff S, Abdulahad WH, van Dijk MC, Limburg PC, Kallenberg CG, Bijl M. Urinary T cells in active lupus nephritis show an effector memory phenotype. Ann. Rheum. Dis. DOI: 10.1136/ard.2009.124636 (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Houssiau FA, D’Cruz D, Vianna J, Hughes GR. Lupus nephritis: the significance of serological tests at the time of biopsy. Clin. Exp. Rheumatol.9(4), 345–349 (1991).
   PubMed Web of Science ®Google Scholar
• Hill GS, Hinglais N, Tron F, Bach JF. Systemic lupus erythematosus. Morphologic correlations with immunologic and clinical data at the time of biopsy. Am. J. Med.64(1), 61–79 (1978).
   PubMed Web of Science ®Google Scholar
• Esdaile JM, Levinton C, Federgreen W, Hayslett JP, Kashgarian M. The clinical and renal biopsy predictors of long-term outcome in lupus nephritis: a study of 87 patients and review of the literature. Q. J. Med.72(269), 779–833 (1989).
   PubMedGoogle Scholar
• Weening JJ, D’Agati VD, Schwartz MM et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int.65(2), 521–530 (2004).
   PubMed Web of Science ®Google Scholar
• Austin HA III, Muenz LR, Joyce KM, Antonovych TT, Balow JE. Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int.25(4), 689–695 (1984).
   PubMed Web of Science ®Google Scholar
• Austin HA, III, Boumpas DT, Vaughan EM, Balow JE. Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data. Kidney Int.45(2), 544–550 (1994).
   PubMed Web of Science ®Google Scholar
• Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann. Rheum. Dis.69(1), 20–28 (2010).
   PubMed Web of Science ®Google Scholar
• Grootscholten C, Berden JH. Discontinuation of immunosuppression in proliferative lupus nephritis: is it possible?. Nephrol. Dial. Transplant.21(6), 1465–1469 (2006).
   PubMed Web of Science ®Google Scholar
• Steinberg AD, Steinberg SC. Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum.34(8), 945–950 (1991).
   PubMed Web of Science ®Google Scholar
• Gourley MF, Austin HA III, Scott D et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann. Intern. Med.125(7), 549–557 (1996).
   PubMed Web of Science ®Google Scholar
• Boumpas DT, Austin HA III, Vaughn EM et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet340(8822), 741–745 (1992).
   PubMed Web of Science ®Google Scholar
• Houssiau FA, Vasconcelos C, D’Cruz D et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum.46(8), 2121–2131 (2002).
   PubMed Web of Science ®Google Scholar
• Houssiau FA, Vasconcelos C, D’Cruz D et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann. Rheum. Dis.69(1), 61–64 (2010).
   PubMed Web of Science ®Google Scholar
• Grootscholten C, Ligtenberg G, Hagen EC et al. Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. Kidney Int.70(4), 732–742 (2006).
   PubMed Web of Science ®Google Scholar
• Grootscholten C, Bajema IM, Florquin S et al. Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis. Arthritis Rheum.56(3), 924–937 (2007).
   PubMed Web of Science ®Google Scholar
• Chan TM, Li FK, Tang CS et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N. Engl. J. Med.343(16), 1156–1162 (2000).
   PubMed Web of Science ®Google Scholar
• Chan TM, Tse KC, Tang CS, Mok MY, Li FK. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J. Am. Soc. Nephrol.16(4), 1076–1084 (2005).
   PubMed Web of Science ®Google Scholar
• Ginzler EM, Dooley MA, Aranow C et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N. Engl. J. Med.353(21), 2219–2228 (2005).
   PubMed Web of Science ®Google Scholar
• Appel GB, Contreras G, Dooley MA et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J. Am. Soc. Nephrol.20(5), 1103–1112 (2009).
   PubMed Web of Science ®Google Scholar
• Bao H, Liu ZH, Xie HL, Hu WX, Zhang HT, Li LS. Successful treatment of class V+IV lupus nephritis with multi target therapy. J. Am. Soc. Nephrol.19(10), 2001–2010 (2008).
   PubMed Web of Science ®Google Scholar
• Isenberg D, Appel GB, Contreras G et al. Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology (Oxford)49(1), 128–140 (2010).
   PubMed Web of Science ®Google Scholar
• Moroni G, Doria A, Mosca M et al. A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years. Clin. J. Am. Soc. Nephrol.1(5), 925–932 (2006).
   PubMed Web of Science ®Google Scholar
• Contreras G, Pardo V, Leclercq B et al. Sequential therapies for proliferative lupus nephritis. N. Engl. J. Med.350(10), 971–980 (2004).
   PubMed Web of Science ®Google Scholar
• Houssiau FA, D’Cruz DP, Sangle SR. Azathioprine versus mycophenolate mofetil for maintenance immunosuppression of proliferative lupus nephritis: results of a randomized trial (MAINTAIN); Presented at: 73rd Annual Scientific Meeting of the American College of Rheumatology. Philadelphia, PA, USA, 19 October 2009.
   Google Scholar
• Zhu B, Chen N, Lin Y et al. Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials. Nephrol. Dial. Transplant.22(7), 1933–1942 (2007).
   PubMed Web of Science ®Google Scholar
• Bhinder S, Singh A, Majithia V. Membranous (class V) renal disease in systemic lupus erythematosus may be more common than previously reported: results of a 6-year retrospective analysis. Am. J. Med. Sci.339(3), 230–232 (2010).
   PubMed Web of Science ®Google Scholar
• Moroni G, Maccario M, Banfi G, Quaglini S, Ponticelli C. Treatment of membranous lupus nephritis. Am. J. Kidney Dis.31(4), 681–686 (1998).
   PubMed Web of Science ®Google Scholar
• Radhakrishnan J, Kunis CL, D’Agati V, Appel GB. Cyclosporine treatment of lupus membranous nephropathy. Clin. Nephrol.42(3), 147–154 (1994).
   PubMed Web of Science ®Google Scholar
• Mercadal L, Montcel ST, Nochy D et al. Factors affecting outcome and prognosis in membranous lupus nephropathy. Nephrol. Dial. Transplant.17(10), 1771–1778 (2002).
   PubMed Web of Science ®Google Scholar
• Austin HA III, Illei GG, Braun MJ, Balow JE. Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J. Am. Soc. Nephrol.20(4), 901–911 (2009).
   PubMed Web of Science ®Google Scholar
• Radhakrishnan J, Moutzouris DA, Ginzler EM, Solomons N, Siempos II, Appel GB. Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis. Kidney Int.77(2), 152–160 (2010).
   PubMed Web of Science ®Google Scholar
• Mok CC, Ying KY, Yim CW, Ng WL, Wong WS. Very long-term outcome of pure lupus membranous nephropathy treated with glucocorticoid and azathioprine. Lupus18(12), 1091–1095 (2009).
   PubMed Web of Science ®Google Scholar
• Rietveld A, Berden JH. Renal replacement therapy in lupus nephritis. Nephrol. Dial. Transplant.23(10), 3056–3060 (2008).
   PubMed Web of Science ®Google Scholar
• Masood S, Jayne D, Karim Y. Beyond immunosuppression – challenges in the clinical management of lupus nephritis. Lupus18(2), 106–115 (2009).
   PubMed Web of Science ®Google Scholar
• de Leeuw K, Freire B, Smit AJ, Bootsma H, Kallenberg CG, Bijl M. Traditional and non-traditional risk factors contribute to the development of accelerated atherosclerosis in patients with systemic lupus erythematosus. Lupus15(10), 675–682 (2006).
   PubMed Web of Science ®Google Scholar
• de Leeuw K, Smit AJ, de Groot E, van Roon AM, Kallenberg CG, Bijl M. Longitudinal study on premature atherosclerosis in patients with systemic lupus erythematosus. Atherosclerosis206(2), 546–550 (2009).
   PubMed Web of Science ®Google Scholar
• Duran-Barragan S, McGwin G Jr, Vila LM, Reveille JD, Alarcon GS. Angiotensin-converting enzyme inhibitors delay the occurrence of renal involvement and are associated with a decreased risk of disease activity in patients with systemic lupus erythematosus – results from LUMINA (LIX): a multiethnic US cohort. Rheumatology (Oxford)47(7), 1093–1096 (2008).
   PubMed Web of Science ®Google Scholar
• Kaiser R, Cleveland CM, Criswell LA. Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort. Ann. Rheum. Dis.68(2), 238–241 (2009).
   PubMed Web of Science ®Google Scholar
• Bhat P, Radhakrishnan J. B lymphocytes and lupus nephritis: new insights into pathogenesis and targeted therapies. Kidney Int.73(3), 261–268 (2008).
   PubMed Web of Science ®Google Scholar
• Emery P, Deodhar A, Rigby WF et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab’s Efficacy in MTX iNadequate rEsponders [SERENE]). Ann. Rheum. Dis.69(9), 1629–1635 (2010).
   PubMed Web of Science ®Google Scholar
• Meijer JM, Pijpe J, Vissink A, Kallenberg CG, Bootsma H. Treatment of primary Sjogren syndrome with rituximab: extended follow-up, safety and efficacy of retreatment. Ann. Rheum. Dis.68(2), 284–285 (2009).
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Diaz-Lagares C, Soto-Cardenas MJ et al. Rituximab therapy in lupus nephritis: current clinical evidence. Clin. Rev. Allergy Immunol. (2010) (Epub ahead of print).
   Google Scholar
• Furie R, Looney RJ, Rovin B. Efficacy and safety of rituximab in subjects with active proliferative lupus nephritis (LN): results from the randomized, double-blind Phase III LUNAR study. Presented at: 73rd Annual Scientific Meeting of the American College of Rheumatology. Philadelphia, PA, USA, 19 October 2009.
   Google Scholar
• Dörner T, Kaufmann J, Wegener WA, Teoh N, Goldenberg DM, Burmester GR. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res. Ther.8(3), R74 (2006).
   PubMed Web of Science ®Google Scholar
• Kremer JM, Genant HK, Moreland LW et al. Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum.58(4), 953–963 (2008).
   PubMed Web of Science ®Google Scholar
• Dolff S, Wilde B, Patschan S et al. Peripheral circulating activated B-cell populations are associated with nephritis and disease activity in patients with systemic lupus erythematosus. Scand. J. Immunol.66(5), 584–590 (2007).
   PubMed Web of Science ®Google Scholar
• Daikh DI, Wofsy D. Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J. Immunol.166(5), 2913–2916 (2001).
   PubMed Web of Science ®Google Scholar
• Aten J, Roos A, Claessen N, Schilder-Tol EJ, Ten Berge IJ, Weening JJ. Strong and selective glomerular localization of CD134 ligand and TNF receptor-1 in proliferative lupus nephritis. J. Am. Soc. Nephrol.11(8), 1426–1438 (2000).
   PubMed Web of Science ®Google Scholar
• Zhou YB, Ye RG, Li YJ, Xie CM. Targeting the CD134–CD134L interaction using anti-CD134 and/or rhCD134 fusion protein as a possible strategy to prevent lupus nephritis. Rheumatol. Int.29(4), 417–425 (2009).
   PubMed Web of Science ®Google Scholar
• Boumpas DT, Furie R, Manzi S et al. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum.48(3), 719–727 (2003).
   PubMed Web of Science ®Google Scholar
• Weisman MH, Bluestein HG, Berner CM, de Haan HA. Reduction in circulating dsDNA antibody titer after administration of LJP 394. J. Rheumatol.24(2), 314–318 (1997).
   PubMed Web of Science ®Google Scholar
• Furie RA, Cash JM, Cronin ME et al. Treatment of systemic lupus erythematosus with LJP 394. J. Rheumatol.28(2), 257–265 (2001).
   PubMed Web of Science ®Google Scholar
• Cardiel MH, Tumlin JA, Furie RA, Wallace DJ, Joh T, Linnik MD. Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled Phase III trial. Arthritis Rheum.58(8), 2470–2480 (2008).
   PubMed Web of Science ®Google Scholar
• Gross JA, Johnston J, Mudri S et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature404(6781), 995–999 (2000).
   PubMed Web of Science ®Google Scholar
• Wallace DJ, Stohl W, Furie RA et al. A Phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum.61(9), 1168–1178 (2009).
   PubMed Web of Science ®Google Scholar
• Gunnarsson I, Sundelin B, Jonsdottir T, Jacobson SH, Henriksson EW, van Vollenhoven RF. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum.56(4), 1263–1272 (2007).
   PubMed Web of Science ®Google Scholar
• Terrier B, Amoura Z, Ravaud P et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum.62(8), 2458–2466 (2010).
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Soto MJ, Cuadrado MJ, Khamashta MA. Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases. Lupus18(9), 767–776 (2009).
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Diaz-Lagares C, Khamashta MA. Rituximab and lupus: good in real life, bad in controlled trials. Comment on the article by Lu et al.Arthritis Rheum.61(9), 1281–1282 (2009).
   PubMed Web of Science ®Google Scholar
• Alexander T, Thiel A, Rosen O et al. Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system. Blood113(1), 214–223 (2009).
   PubMed Web of Science ®Google Scholar
• Liang J, Zhang H, Hua B et al. Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study. Ann. Rheum. Dis.69(8), 1423–1429 (2010).
   PubMed Web of Science ®Google Scholar
• Sun L, Wang D, Liang J et al. Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus. Arthritis Rheum.62(8), 2467–2475 (2010).
   PubMed Web of Science ®Google Scholar